Similar Companies:
Abeome Corporation
USA
Privately Held
Abeome is a privately-held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.
Cinnagen
Iran
n/a
CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products to cover regional markets. Enzymes, molecular biology reagents and PCR kits were the first products and then CinnaGen used its proprietary set of technologies to endow monoclonal antibodies for blood group typing. The next important step for CinnaGen was to enter therapeutic recombinant proteins and monoclonal antibodies area.
SpikImm
France
Privately Held
SpikImm SAS is developing anti-SARS-CoV-2 (Covid-19) monoclonal antibodies for therapeutic and diagnostic use. This immunotherapy offers several therapeutic advantages which have already been proven in clinical trials. Antibodies developed by SpikImm have been generated in the laboratory of Humoral Immunology at the Institut Pasteur through an innovative process enabling the screening and selection of human SARS-CoV-2 neutralizing antibodies. An international patent application has been filed by the Institut Pasteur.
ABOLOGIX
Switzerland
Privately Held
ABOLOGIX is developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3). Blocking JAM-C is a novel approach for the treatment of non-Hodgkin´s lymphoma. Olfml3 is a proangiogenic factor in the tumor microenvironment, being released by endothelial cells and pericytes. Blocking Olfml3 can lead to a new generation of angiogenic inhibitors. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the Université de Genève and the Hôpitaux Universitaires de Genève.
Mabion
Poland
n/a
Mabion S.A. is the first Polish biotechnology company and the only one in the country that has the innovation among its achievements. It was established in March 2007. On the basis of the Company’s creation laid the idea of ??initiating activities in the area of ??the economy founded on knowledge and technology. Mabion is based on the concept of combination of the latest achievements in science, research, technological and analytical projects management and implementation of the innovative management involving integration of science, technological and managerial knowledge.The core business is the development and implementation of the latest generation of biotech drugs based on monoclonal antibody technology.This therapeutic class is today a foundation to combat the most serious diseases thanks to two unique features - the specificity and safety.These drugs have the ability to recognize a cancer causing factor and to interact selectively only with it. This feature fits in with the concept of targeted therapies, in line with the global trend of personalized medicine.Another benefit to the patient is an extremely low toxicity of the therapy. It is obtained through a proper engineering of the drug’s structure, resembling the molecule of a patient's organism. As a result, the immune system treats the antibody protein as its own.
PlantiBodies
Unknown
Privately Held
Plantibodies is a unique biotech company dedicated to the development and production of plant based monoclonal antibodies to cure life threatening diseases such as cancers, neurodegenerative diseases, and autoimmune diseases.
Website: https://flame.bio/
Develops clinical-stage biopharmaceutical therapies targeting chronic inflammation-related diseases such as cancer, cardiovascular disease, and arthritis, focusing on IL-1ß neutralizing antibodies and inflammasome control.
VentureRadar Research / Company Website
Flame Biosciences is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that address major unmet needs in diseases that are linked to chronic inflammation including cancer, atherosclerotic cardiovascular disease and arthritis. Flame is developing IL-1ß neutralizing antibodies that are focused on the inflammasome, which is the primary means through which the innate immune system controls inflammation.
VentureRadar Research / Company Website
Associated sectors:
Biotechnology; Monoclonal Antibodies; Biotech;